These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 235644)

  • 21. Beta-adrenergic blocking agents. 20. (3-Hydroxyprop-1-enyl)-substituted 1-(aryloxy)-3-(alkylamino)propan-2-ols.
    Tucker H
    J Med Chem; 1980 Oct; 23(10):1122-6. PubMed ID: 6106716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Beta-1 and beta-2 blocking activities of a new series of (arylalkoxy) propanolamines].
    Rosell G; Mauleón D; Pujol MD; Granados R
    Arch Farmacol Toxicol; 1986 Apr; 12(1):65-70. PubMed ID: 2874776
    [No Abstract]   [Full Text] [Related]  

  • 23. Ultra-short-acting beta-adrenergic receptor blocking agents. 2. (Aryloxy)propanolamines containing esters on the aryl function.
    Erhardt PW; Woo CM; Anderson WG; Gorczynski RJ
    J Med Chem; 1982 Dec; 25(12):1408-12. PubMed ID: 6130154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacologic evaluation of CI-775, a cardioselective beta adrenergic antagonist.
    Hastings SG; Smith RD; Corey RM; Essenburg AD; Pettway CE; Tessman DK
    Arch Int Pharmacodyn Ther; 1977 Mar; 226(1):81-99. PubMed ID: 17372
    [No Abstract]   [Full Text] [Related]  

  • 25. beta-Adrenergic blocking agents. 18. 1-(Aryloxy)-3-(arylthioalkylamino)propan-2-ols and 1-substituted alkylthioamino-3-(aryloxy)propan-2-ols.
    Tucker H; Coope JF
    J Med Chem; 1978 Aug; 21(8):769-73. PubMed ID: 29123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beta-adrenergic receptor blocking properties of three allyl-substituted phenoxypropanolamines.
    Ablad B; Brogård M; Carlsson E; Ek L
    Eur J Pharmacol; 1970; 13(1):59-64. PubMed ID: 4395676
    [No Abstract]   [Full Text] [Related]  

  • 27. Pyridine isosteres of the -adrenergic antagonists, 2-(p-nitrophenyl)-1-isopropylamino-2-ethanol and 3-(p-nitrophenoxy)-1-isopropylamino-2-propanol.
    Gnewuch CT; Friedman HL
    J Med Chem; 1972 Dec; 15(12):1321-4. PubMed ID: 4404591
    [No Abstract]   [Full Text] [Related]  

  • 28. The beta-blocking potency and cardioselectivity of tolamolol and its isomers in rodents.
    Adam KR; Baird JR; Burges RA; Linnell J
    Eur J Pharmacol; 1974 Feb; 25(2):170-5. PubMed ID: 4154851
    [No Abstract]   [Full Text] [Related]  

  • 29. Non-catechol phenylethanolamines: agonistic and antagonistic actions on beta-adrenoreceptors in isolated tissues from the guinea-pig.
    Malta E; Raper C
    Clin Exp Pharmacol Physiol; 1974; 1(3):259-68. PubMed ID: 4156504
    [No Abstract]   [Full Text] [Related]  

  • 30. Conformation effects on the activity of drugs. 4. Cyclic analogs of 1-(p-nitrophenyl)-2-isopropylaminoethanol. Synthesis and evaluation of the adrenergic beta-receptor blocking activity of 2-(p-nitrophenyl)-4-isopropylmorpholine.
    Balsamo A; Crotti P; Macchia B; Macchia F; Del Tacca M; Mazzanti L
    J Med Chem; 1973 Mar; 16(3):224-7. PubMed ID: 4147387
    [No Abstract]   [Full Text] [Related]  

  • 31. beta-Adrenergic blocking agents. 16. 1-(Acylaminomethyl-, ureidomethyl-, and ureidoethylphenoxy)-3-amino-2-propanols.
    Smith LH
    J Med Chem; 1977 Oct; 20(10):1254-8. PubMed ID: 20502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beta-Adrenergic blocking agents. 15. 1-Substituted ureidophenoxy-3-amino-2-propanols.
    Smith LH
    J Med Chem; 1977 May; 20(5):705-8. PubMed ID: 16137
    [No Abstract]   [Full Text] [Related]  

  • 33. An analysis of the B-adrenergic action of oxyfedrine.
    Sakai K; Shiraki Y; Hashimoto K
    Eur J Pharmacol; 1973 Jan; 21(1):81-8. PubMed ID: 4145385
    [No Abstract]   [Full Text] [Related]  

  • 34. Development of a highly cardioselective ultra short-acting beta-blocker, ONO-1101.
    Iguchi S; Iwamura H; Nishizaki M; Hayashi A; Senokuchi K; Kobayashi K; Sakaki K; Hachiya K; Ichioka Y; Kawamura M
    Chem Pharm Bull (Tokyo); 1992 Jun; 40(6):1462-9. PubMed ID: 1356643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The assessment of -adrenoceptor blocking potency and cardioselectivity in vitro and in vivo.
    Baird JR; Linnell J
    J Pharm Pharmacol; 1972 Nov; 24(11):880-5. PubMed ID: 4405651
    [No Abstract]   [Full Text] [Related]  

  • 36. A new series of cardioselective adrenergic beta-receptor blocking compounds. 1-(2-Acyl-4-acylaminophenoxy)-3-isopropylaminopropan-2-ols.
    Basil B; Clark JR; Coffee EC; Jordon R; Loveless AH; Pain DL; Wooldridge KR
    J Med Chem; 1976 Mar; 19(3):399-402. PubMed ID: 3647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beta-adrenoceptor stimulant properties of amidoalkylamino-substituted 1-aryl-2-ethanols and 1-(aryloxy)-2-propanols.
    Barlow JJ; Main BG; Snow HM
    J Med Chem; 1981 Mar; 24(3):315-22. PubMed ID: 6115058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nitrilophenoxypropanolamines: influence of ring substitution on beta-receptor blockade.
    Mylecharane EJ; Raper C
    Eur J Pharmacol; 1974 Nov; 29(1):93-101. PubMed ID: 4154862
    [No Abstract]   [Full Text] [Related]  

  • 39. Synthesis, pharmacological activity and chromatographic separation of some novel potential beta-blockers of the aryloxyaminopropanol type.
    Cizmáriková R; Racanská E; Hrobonova K; Lehotay J; Aghová Z; Halesová D
    Pharmazie; 2003 Apr; 58(4):237-41. PubMed ID: 12749403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ultra-short-acting beta-adrenergic receptor blocking agents. 1. (Aryloxy)propanolamines containing esters in the nitrogen substituent.
    Erhardt PW; Woo CM; Gorczynski RJ; Anderson WG
    J Med Chem; 1982 Dec; 25(12):1402-7. PubMed ID: 6130153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.